Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?

By  

HEPATOLOGY, Vol. 62, Iss. 2, 2015-08 ,pp. : 660-661

John Wiley & Sons Inc

Access to resources Recommend Favorite

Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co‐infected patients

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 1, 2015-01 ,pp. : 25-36

John Wiley & Sons Inc

Access to resources Recommend Favorite

The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 3, 2015-03 ,pp. : 254-262

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dyspnoea in patients with chronic hepatitis C treated with pegylated interferon and ribavirin

By Garib Junia Rios   Garcia Guilherme Freire   Teixeira Rosâângela   Lima e Silva Francisco das Chagas  

Scandinavian Journal of Infectious Diseases, Vol. 43, Iss. 8, 2011-08 ,pp. : 625-631

Informa Healthcare

Access to resources Recommend Favorite

Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis

By Sabbatani Sergio   Manfredi Roberto   Marinacci Ginevra   Pavoni Michele   Cristoni Lorenzo   Chiodo Francesco  

Scandinavian Journal of Infectious Diseases, Vol. 38, Iss. 3, 2006-03 ,pp. : 205-208

Informa Healthcare

Access to resources Recommend Favorite